Hence then, the article about casi pharmaceuticals announces plan to submit ind application for cid 103 an anti cd 38 antibody in antibody mediated rejection and receipt of a non binding proposal to acquire entire china business of the company was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company )
Also on site :
- Belgium corrects US on ‘peace board’ claim
- Why is South Africa upset about Iran joining BRICS naval drills?
- Numbrix 9 - January 23